Hatchtech appoints Tim Waugh as ceo

Formerly with Roche in the US as a divisional vice president

Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.

Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.

Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’

DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.

Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.

Waugh will join the Board of Hatchtech and will be based in New Jersey, US.

You may also like

Manufacturing

Streamlining bioconjugation for next-generation ADC development

Abzena’s proprietary ThioBridge™ technology delivers precision, scalability, and enhanced stability for antibody-drug conjugates
Manufacturing

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)

Discover how emerging technologies and expert insights are shaping the future of pharma manufacturing
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

A pharmacodynamic analysis platform for targeted protein degrader drugs

Targeted protein degraders (TPDs) are an emerging class of therapeutics that harness a cell’s built-in waste removal process to eliminate disease-causing proteins
Manufacturing

Thermo Fisher Scientific highlights its new accelerator drug development solutions at CPHI Frankfurt 2025

The company has also announced a collaboration with OpenAI as well as a new digital toolbox, OSDPredict, which combines AI and machine learning models to predict formulation behaviour in small-molecule development
Manufacturing

Indena showcases expanded capabilities, innovative APIs and ADC partnership at CPHI 2025

Indena, a global leader in plant-derived active pharmaceutical ingredients (APIs), will present its latest technological and manufacturing advances at CPHI 2025 (Frankfurt, 28–30 October)
Manufacturing

SGD Pharma presents new innovations at CPHI Frankfurt 2025

SGD Pharma, a global leader in pharmaceutical glass primary packaging solutions, will showcase its enhanced portfolio of products and services at booth 8.0H24 during CPHI, taking place in Frankfurt, Germany, from 28–30 October
Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Subscribe now